Search for: "E Merck" Results 141 - 160 of 393
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Jun 2013, 6:23 pm
Data from the first of those trials is expected later in 2013, Bristol-Myers said in an e-mail. [read post]
5 Jun 2013, 5:29 am by Schachtman
Sander Greenland and others have raised various theoretical objections to the argument that relative risks should exceed two before attribution can be made in specific cases. [read post]
8 Apr 2013, 12:33 pm by Tom Lamb
[Judge Pisano] granted [Merck's] bid to block evidence about e-mails containing opinions of non-Merck employees regarding the drug’s effectiveness, calling them “inadmissible hearsay. [read post]
18 Mar 2013, 8:08 am by Ed. Microjuris.com Puerto Rico
José Rivera, presidente E-Cycling Viernes, 22 de marzo de 2013 Panel: Situación Actual y Futura: Manejo de los Desperdicios Sólidos y Reciclaje en Puerto Rico Lcdo. [read post]
28 Feb 2013, 11:08 am by Doug Cornelius
The SEC argued for the benefit of the discovery rule, which had been used in Merck & Co. v. [read post]
28 Feb 2013, 11:08 am by Doug Cornelius
The SEC argued for the benefit of the discovery rule, which had been used in Merck & Co. v. [read post]
25 Feb 2013, 9:26 pm by Aaron Barkoff
 Momenta further argues that both Classen and Momenta are inconsistent with the statutory text and Supreme Court precedents, including the Court's most recent case interpreting the safe harbor, Merck v. [read post]
12 Feb 2013, 8:57 am by Lawrence B. Ebert
See In re Keller, 642 F.2d 413, 426 (CCPA 1981) (“one cannot show non-obviousness by attacking references individually where, as here, the rejections are based on combinations of references”); see also In re Merck & Co., 800 F.2d 1091, 1097 (Fed. [read post]
9 Nov 2012, 6:54 am
Fosamax ONJ Claims There are Fosamax jaw necrosis lawsuits that are pending against Merck & Co. over their oral bisphosphonate medication. [read post]
27 Jul 2012, 3:02 am by Ken Lopez
He does a good job of diffusing the “CSI Effect” and discussing the concept of preponderance of the evidence and calls Merck's executives “Desperate Executives. [read post]